Prostate, breast and gynecological cancer markers RAK with homology to HIV-1

Cancer Letters

Volumn 124, Issue 2, 1998, Pages 213-223

  Rakowicz Szulczynska, Eva M ^a   Jackson, Betty ^a   Snyder, William ^a  

^a UNIVERSITY OF NEBRASKA AT OMAHA   (United States)

Author keywords

Cancer of the reproductive system; Diagnostic markers; HIV 1 homology

Indexed keywords

CA 125 ANTIGEN; TUMOR MARKER;

ARTICLE; BREAST CANCER; GENE AMPLIFICATION; GENOME; GYNECOLOGIC CANCER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN TISSUE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; UNIDENTIFIED RETROVIRUS;

EID: 0032570765     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(97)00483-7     Document Type: Article

References (29)

1. R.S. Kirby, T.J. Christmas, M. Brawer, Prostate Cancer, Times Mirror International, London, 1996.
2. Stock R.G., Stone N.N., Ianuzzi C., Unger P. Seminal vesicle biopsy and laparoscopic pelvic lymph node dissection: implications for patient selection in the radiotherapeutic management of prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 33:1995;815-821.
3. Carter H.B., Coffey D.S. The prostate: an increasing medical problem. Prostate. 16:1990;39-48.
4. Schroder F.H. Prostate cancer: to screen or not to screen. Br. Med. J. 306:1993;407-408.
5. Garfinkel L., Boring C.C., Heath C.W. Jr. Changing trends. An overview of breast cancer incidence and mortality. Cancer. 74:1994;222-227.
6. Miki Y., Swensen J., Shattuck-Eidens D.et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 226:1994;66.
7. Wooster R., Neuhausen S., Mangion J.et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science. 265:1994;2088-2090.
8. Nowak R. Breast cancer gene offers surprises. Science. 265:1994;1796-1799.
9. Senie R.T., Lesser M., Kinne D.W., Rosen P.P. Method of tumor detection influences disease-free survival of women with breast carcinoma. Cancer. 73:1994;1666-1672.
10. Solin L.J., Legorreta A., Schultz D.J., Zatz S., Goodman R.L. The importance of mammographic screening relative to the treatment of women with carcinoma of the breast. Arch. Intern. Med. 154:1994;745-752.
11. Rakowicz-Szulczynska E.M., Markowski M., Mackiewicz A., Karczewska A., Snyder W., McIntosh D.G., Kapcinska M., Smith M.L. New protein and PCR markers RAK for diagnosis, prognosis and surgery guidance for breast cancer. Cancer Lett. 112:1997;93-101.
12. E.M. Rakowicz-Szulczynska, W. Kaczmarski, K.S. Steimer, P.J. Durda, Internalized antibodies as a potential tool against retroviral diseases, in: E.M. Rakowicz-Szulczynska (Ed.), Nuclear Localization of Growth Factors and of Monoclonal Antibodies, CRC Press, Boca Raton, FL, 1993.
13. Rakowicz-Szulczynska E.M., McIntosh D.G., Morris P., Smith M. Novel family of gynecological cancer antigens detected by anti-HIV antibody. Infect. Dis. Obstet. Gynecol. 2:1994;171-178.
14. Rakowicz-Szulczynska E.M., Perry M.J., McIntosh D.G., Smith M.L. Mechanisms of cancer growth promotion by HIV-1 neutralizing antibodies. Cancer J. 8:1995;143-149.
15. Rakowicz-Szulczynska E.M., McIntosh D.G., Perry M.J., Smith M.L. Nuclear antigens with epitopic homology to the cell surface antigens: the neglected determinants of malignant transformation. Antibodies Immunoconjugates Radiopharmaceuticals. 8:1995;261-279.
16. Rakowicz-Szulczynska E.M., Roszek A., Mackiewicz A., Markowska J., McIntosh D.G., Karczewska A., Snyder W., Leary D., Smith M.L. Diagnostic evaluation of FCV/RAK cancer markers. I. Cervical and ovarian cancer. Int. J. Oncol. 9:1996;693-699.
17. Rakowicz-Szulczynska E.M., Perry M.J., McIntosh D.G., Smith M.L. Antigen RAK: a new breast cancer diagnostic marker. J. Tumor Marker Oncol. 10:1995;24-37.
18. Armenian N.K., Lilienfeld A.M., Diamond E.L.et al. Relation between benign prostatic hyperplasia and cancer of the prostate: a prospective and retrospective study. Lancet. 2:1974;115-117.
19. Bonkhoff H., Remberger K. Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: a stem cell model. Prostate. 28:1996;98-106.
20. Zermann D.H., Lindner H., Bockhorn V., Schubert J. The high risk patient with symptomatic prostatic hyperplasia - a therapeutic dilemma? Z. Arztl. Fortbild Jena. 89:1995;287-292.
21. Schambeck C.M. Evaluation of the COBAS CORE immunoassay for measuring prostate-specific antigen (PSA) - multi-centre study results. The PSA Study Group. Eur. J. Clin. Chem. Clin. Biochem. 33:1995;541-547.
22. Nishiya M., Miller G.J., Lookner D.H., Crawford E.D. Prostate specific antigen density in patients with histologically proven prostate carcinoma. Cancer. 74:1994;3002-3009.
23. Herbert J.T., Birkhoff J.D., Feorino P.M.et al. Herpes simples virus type 2 and cancer of the prostate. J. Urol. 116:1976;1608-1611.
24. Centifano Y.M., Kaufman H.E., Zam Z.S.et al. Herpes virus particles in prostate cancer cells. J. Virol. 12:1973;1608.
25. McCombs R.M. Role of oncornaviruses in carcinoma of the prostate. Cancer Treatment Rep. 61:1977;131.
26. Feminella J.J., Lattimer J.K. An apparent increase in genital carcinomas among wives of men with prostatic carcinoma: an epidemiologic survey. Pirquet Bull. Clin. Med. 20:1974;3-9.
27. Andersson M.L., Medstrand P., Yin H., Blomberg J. Differential expression of human endogenous retroviral sequences similar to mouse mammary tumor virus in normal peripheral blood mononuclear cells. AIDS Res. Hum. Retroviruses. 12:1996;833-840.
28. Litvinov S.V., Riabykh T.P., Kriukova I.N., Apraskina A.V. Antibodies interacting with the proteins of the mammary cancer virus (MMTV) in the sera of healthy women. Biull. Eksp. Biol. Med. 103:1987;194-196.
29. Breslow N., Chan C.W., Dhom C.et al. Latent carcinoma of the prostate at autopsy in seven areas. Int. J. Cancer. 20:1977;680-688.